Omnicell Inc is primarily active in the healthcare industry.

Omnicell Inc faces competition from various companies in the market. Some of its main competitors include McKesson Corporation, BD (Becton, Dickinson and Company), and Cantel Medical Corp. These companies operate in the healthcare solutions industry and provide similar products and services, which directly compete with Omnicell Inc. Additionally, companies like Capsa Healthcare and Baxter International Inc. also pose competition in certain segments. However, Omnicell Inc's strong market presence, innovative technologies, and comprehensive range of solutions help them remain competitive in the industry.

Omnicell Inc, a leading provider of medication management solutions, has a rich history and background. Established in 1992, Omnicell has continuously delivered innovative technologies to enhance patient safety and improve healthcare outcomes. The company's journey started with automated dispensing systems for medication storage and administration. Over the years, Omnicell expanded its product portfolio to include advanced solutions like robotic automation, analytics, and interoperability, catering to various healthcare settings globally. Today, Omnicell is renowned for its commitment to optimizing medication management processes, reducing errors, improving efficiency, and enabling healthcare professionals to focus on patient care. With a strong track record and dedication to innovation, Omnicell Inc has established itself as a trusted name in the healthcare industry.

Omnicell Inc has achieved several significant milestones since its inception. The company has become a global leader in automated healthcare solutions, catering to hospitals, pharmacies, and healthcare organizations. Omnicell's product portfolio includes advanced medication management systems, robotics, and software solutions improving patient safety and operational efficiency. The company has successfully expanded its global presence, established strategic partnerships, and received multiple industry accolades. Moreover, Omnicell has consistently focused on research and development, resulting in innovative technologies and improved patient outcomes. With its dedication to advancing healthcare through technology, Omnicell Inc continues to drive positive change in the industry.

Omnicell Inc is primarily present in the United States.

Omnicell Inc represents a strong commitment to improving patient care and safety through innovative medication management solutions. The company's corporate philosophy revolves around optimizing workflows and ensuring the right medication is delivered to the right patient at the right time. Omnicell is dedicated to enhancing operational efficiency, reducing medication errors, and promoting adherence to medication regimens. Their values include prioritizing patient-centricity, fostering a culture of collaboration, and driving continuous innovation in healthcare technology. Omnicell Inc strives to revolutionize medication management processes, ultimately helping healthcare organizations deliver better patient outcomes and improve overall healthcare efficiency.

Analysts currently set an average price target of 57,56 USD for the Omnicell stock (median: 55,08 USD), implying +58,0 % versus the latest price. The consensus is based on 14 analyst ratings.

Omnicell Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Omnicell stock: 11 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Omnicell to generate revenue of 1,24 Mrd. USD and earnings per share of 2,29 USD.

Omnicell Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Omnicell share trades at 32,22 EUR (37,30 USD).

The Omnicell share (OMCL) is listed on 5 stock exchanges, including: NASDAQ (OMCL), Frankfurt (OC9.F), München (OC9.MU), Düsseldorf (OC9.DU), SIX (Zürich) (OC9.SW).

Omnicell Inc. is a US-based company that has gained worldwide recognition for its automation solutions for healthcare providers. The company positions itself as a reliable provider of innovative products and services in this field. The main products and services of Omnicell Inc. fall into four main areas: medication management, central pharmacy systems, workflow optimization, and analytics solutions. The medication management is the core of Omnicell Inc.'s business model. The company offers a variety of solutions for various areas including hospitals, pharmacies, and long-term care facilities to better automate medication inspection, preparation, dispensing, and returns. These solutions help nursing staff save time, minimize errors, and better meet patient needs. Central pharmacy systems are another important pillar of Omnicell Inc. These systems are designed to automate the workflow of pharmacies and distribution centers by monitoring and managing inventory and orders, optimizing product assignment to patients, and providing real-time data for inventory management. Workflow optimization is an important aspect of Omnicell Inc.'s business model. The company aims to increase the efficiency of nursing staff by automating workflows, reducing workload, and improving the quality of patient care. The company has developed a wide range of solutions for this purpose, including automated documentation, inventory management, and patient assignment. Analytics solutions also play an important role in Omnicell Inc.'s business strategy. The company offers innovative analysis tools that monitor prescription dispensing and collect data to optimize medication inventory and orders. These tools provide important business-relevant information that contributes to higher ROI in the healthcare industry. Overall, the company offers a wide range of products and services aimed at increasing efficiency, accuracy, and effectiveness in healthcare. Omnicell Inc. aims to meet the needs of providers and patients alike while ensuring the highest level of reliability, efficiency, and safety. With its innovative products, strong focus on customer service, and continuous investment in research and development, Omnicell Inc. has established itself as a market leader in automation solutions for healthcare providers.

odotettu liikevaihto Omnicell on 1,24 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Omnicell on 103,09 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Omnicell:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,27. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Omnicell-osakkeen arvostusta.

Omnicell:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,36. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Omnicell-osakkeen arvostuskennuslukuna.

Omnicell:n Eulpool-laatuscore on 3/10.

Omnicell:n ISIN on US68213N1090. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Omnicell:n WKN on 632313. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Omnicell:n ticker on OMCL. Tämä pörssinoteeraus käytetään Omnicell-osakkeiden kauppaan pörssissä.

Omnicell maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Omnicell kuuluu sektoriin 'Terveydenhuolto'.

Omnicell:n osingot jaetaan valuutassa USD.